Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TFX 06

Next Previous
X
Search
Drug Profile

TFX 06

Alternative Names: TFX-06

Latest Information Update: 14 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Yangli Pharmaceutical Technology
  • Class Antineoplastics
  • Mechanism of Action Estrogen receptor alpha degradation enhancers; Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II HER2 negative breast cancer

Most Recent Events

  • 05 Dec 2023 Interim adverse events, efficacy and pharmacokinectics data from a phase-I/II trial in HER2-negative-breast-cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
  • 17 Apr 2023 Phase-I/II clinical trials in HER2-negative-breast-cancer (Late-stage disease, Monotherapy, Metastatic disease, In adults, In the elderly, Second-line therapy or greater) in China (PO) (NCT05927779)
  • 14 Apr 2023 Preclinical trials in HER2-negative-breast-cancer in China (PO) prior to April 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top